ImpediMed Secures $15m Growth Capital Funding
ImpediMed has secured a five-year $15 million growth capital facility from SWK Holdings (NASDAQ:SWKH) to support its commercialization efforts. The company's SOZO® Digital Health Platform, the only FDA-cleared bioimpedance spectroscopy (BIS) technology for breast cancer-related lymphedema (BCRL) assessment, currently has U.S. health payor coverage for over 258 million lives.
The funding strengthens ImpediMed's capital base for executing its commercial strategy. In 2024, the National Accreditation Program for Breast Centers (NABPC) updated its standards to include lymphedema prevention programs using BIS, validating the technology's importance in lymphedema management and creating expansion opportunities for SOZO across breast cancer centers nationwide.
ImpediMed ha ottenuto un finanziamento di crescita di 15 milioni di dollari da SWK Holdings (NASDAQ:SWKH) per sostenere i suoi sforzi di commercializzazione. La piattaforma di salute digitale SOZO®, l'unica tecnologia di spettroscopia bioimpedenza (BIS) approvata dalla FDA per la valutazione del linfedema correlato al cancro al seno (BCRL), attualmente ha una copertura da parte dei pagatori sanitari statunitensi per oltre 258 milioni di vite.
Il finanziamento rafforza la base di capitali di ImpediMed per l'esecuzione della sua strategia commerciale. Nel 2024, il Programma Nazionale di Accreditamento per i Centri per il Cancro al Seno (NABPC) ha aggiornato i suoi standard per includere programmi di prevenzione del linfedema utilizzando la BIS, convalidando l'importanza della tecnologia nella gestione del linfedema e creando opportunità di espansione per SOZO nei centri per il cancro al seno a livello nazionale.
ImpediMed ha obtenido una instalación de capital de crecimiento de 15 millones de dólares de SWK Holdings (NASDAQ:SWKH) para apoyar sus esfuerzos de comercialización. La plataforma de salud digital SOZO®, la única tecnología de espectroscopia de bioimpedancia (BIS) aprobada por la FDA para la evaluación del linfedema relacionado con el cáncer de mama (BCRL), actualmente tiene cobertura de pagadores de salud de EE. UU. para más de 258 millones de vidas.
La financiación fortalece la base de capital de ImpediMed para ejecutar su estrategia comercial. En 2024, el Programa Nacional de Acreditación para Centros de Cáncer de Mama (NABPC) actualizó sus estándares para incluir programas de prevención del linfedema utilizando BIS, validando la importancia de la tecnología en la gestión del linfedema y creando oportunidades de expansión para SOZO en centros de cáncer de mama en todo el país.
ImpediMed는 상업화 노력을 지원하기 위해 SWK Holdings(NASDAQ:SWKH)로부터 1500만 달러의 성장 자본 조달을 확보했습니다. 회사의 SOZO® 디지털 건강 플랫폼은 유일하게 FDA 승인을 받은 유방암 관련 림프부종(BCRL) 평가를 위한 생체 임피던스 분광법(BIS) 기술로, 현재 미국의 건강 보장자가 2억 5800만명의 생명을 보장하고 있습니다.
이번 자금 조달은 ImpediMed의 상업적 전략을 실행하기 위한 자본 기반을 강화합니다. 2024년, 국가 유방센터 인증 프로그램(NABPC)은 BIS를 사용한 림프부종 예방 프로그램을 포함하도록 기준을 업데이트 하여, 림프부종 관리에서 기술의 중요성을 검증하고, 전국의 유방암 센터에서 SOZO의 확장 기회를 창출하고 있습니다.
ImpediMed a sécurisé un financement de croissance de 15 millions de dollars sur cinq ans de la part de SWK Holdings (NASDAQ:SWKH) pour soutenir ses efforts de commercialisation. La plateforme de santé numérique SOZO®, la seule technologie de spectroscopie par bioimpédance (BIS) approuvée par la FDA pour l'évaluation du lymphoedème lié au cancer du sein (BCRL), bénéficie actuellement d'une couverture de payeurs de santé américains pour plus de 258 millions de vies.
Ce financement renforce la base de capitaux d'ImpediMed pour exécuter sa stratégie commerciale. En 2024, le Programme National d'Agrément des Centres de Lutte contre le Cancer du Sein (NABPC) a mis à jour ses normes pour inclure des programmes de prévention du lymphoedème utilisant la BIS, validant ainsi l'importance de la technologie dans la gestion du lymphoedème et créant des opportunités d'expansion pour SOZO dans les centres de lutte contre le cancer du sein à l'échelle nationale.
ImpediMed hat von SWK Holdings (NASDAQ:SWKH) eine fünfjährige 15 Millionen Dollar Wachstumskapitalfinanzierung gesichert, um seine Kommerzialisierungsanstrengungen zu unterstützen. Die SOZO® Digital Health Platform des Unternehmens, die einzige von der FDA zugelassene Bioimpedanzspectroskopie (BIS)-Technologie zur Beurteilung von mit Brustkrebs verwandtem Lymphödem (BCRL), hat derzeit eine Abdeckung durch US-Gesundheitszahler für über 258 Millionen Leben.
Die Finanzierung stärkt die Kapitalbasis von ImpediMed zur Umsetzung seiner kommerziellen Strategie. Im Jahr 2024 aktualisierte das Nationale Akkreditierungsprogramm für Brustzentren (NABPC) seine Standards, um Programme zur Prävention von Lymphödemen unter Verwendung von BIS einzuschließen, was die Bedeutung der Technologie im Lymphödem-Management validiert und Expansionsmöglichkeiten für SOZO in Brustkrebszentren im ganzen Land schafft.
- Secured $15 million growth capital facility over 5 years
- Coverage by U.S. health payors for over 258 million lives
- Only FDA-cleared BIS technology for BCRL assessment
- NABPC inclusion of BIS in accreditation standards creates expansion opportunities
- None.
Insights
This
Several key factors make this investment particularly noteworthy:
- ImpediMed's SOZO platform has achieved critical regulatory clearance (FDA) and widespread payor acceptance, covering 258 million lives
- The recent NAPBC accreditation standard update creates a compelling growth catalyst by essentially mandating BIS technology for breast cancer centers
- The lymphedema detection market shows significant expansion potential, driven by increasing cancer survival rates and focus on early intervention
For SWK Holdings, this deal strengthens their portfolio in the digital health space while maintaining their risk-adjusted return profile through secured lending to commercial-stage companies. The timing is particularly advantageous given the NAPBC's recent standard updates, which should accelerate SOZO platform adoption across breast cancer centers nationwide. This positions SWK to potentially benefit from both regular interest income and the upside of ImpediMed's market expansion.
The significance of ImpediMed's SOZO platform extends beyond its innovative technology - it addresses a critical gap in cancer care. Early lymphedema detection can prevent progression to chronic stages, potentially reducing healthcare costs and improving patient outcomes. The platform's BIS technology offers several distinct advantages:
- Non-invasive monitoring capability that enables regular screening
- Early detection of fluid changes before visible symptoms appear
- Quantitative measurements that allow for objective tracking of patient status
The NAPBC's decision to include BIS in accreditation standards represents a pivotal market catalyst. This effectively establishes BIS as the standard of care for lymphedema management in breast cancer centers. Given that approximately 1 in 5 breast cancer patients develop lymphedema, the addressable market is substantial and growing.
The
New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema.
With this new funding in place, ImpediMed's capital base is well equipped to support the continued execution of its commercial strategy. As a result, the company is better positioned than ever to achieve its long-term goals and create significant value for its shareholders.
As a pioneer in the field of lymphedema detection and monitoring, ImpediMed offers the only FDA-cleared bioimpedance spectroscopy (BIS) technology for the clinical assessment of breast cancer-related lymphedema (BCRL) –– the SOZO® Digital Health Platform. ImpediMed's platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with
Lymphedema, a common consequence of cancer treatment, is challenging to detect before symptoms appear. ImpediMed's SOZO® Digital Health Platform uses BIS to identify fluid changes early, enabling intervention before lymphedema becomes a chronic condition. With growing adoption in clinical practice and increasing payor coverage, ImpediMed's innovative approach is transforming lymphedema management.
In 2024, the National Accreditation Program for Breast Centers (NABPC) updated its accreditation standards to include lymphedema prevention programs utilizing BIS as an evidence-based guideline for managing lymphedema. The NAPBC is a quality program of the American College of Surgeons, and accredited programs must understand, implement, and demonstrate compliance with accreditation standards outlined in Optimal Resources for Breast Care. This recognition further validates BIS as a critical tool in lymphedema management and presents a significant opportunity for ImpediMed to expand its reach, driving broader adoption of the SOZO Digital Health Platform across breast cancer centers nationwide.1
"We are pleased with our agreement with SWK Holdings and the confidence they have shown in ImpediMed, as well as in the future of our SOZO Digital Health Platform," said Dr. Parmjot Bains, MD, CEO & Managing Director of ImpediMed. "SWK's proven approach of supporting innovative healthcare companies makes them an ideal partner for us as we pursue our commercial growth strategy over the next five years. We are confident with the business' direction, and this was reinforced throughout our due diligence process. In conjunction with our existing cash reserves, this facility gives us the time and funding flexibility required to execute on our business plan and fully capitalize on the BCRL opportunity."
"We believe that the SOZO Digital Health Platform is revolutionizing how clinicians assess and manage fluid and body composition, ultimately improving patient outcomes," said JD Tamas, Director of Underwriting at SWK Holdings. "We are excited to provide this capital to support ImpediMed's continued mission to improve the lives of patients by pushing the boundaries of what's possible in fluid and tissue analysis."
About SOZO Digital Health Platform
SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device.
About SWK Holdings
SWK Holdings is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from
About Armentum Partners
Armentum Partners is an investment bank dedicated to assisting healthcare and technology companies access non-dilutive capital. Since the beginning of 2023, Armentum has raised over
About ImpediMed
Founded in
In March 2024, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.
For more information, visit www.impedimed.com.
1 Used with permission of the American College of Surgeons,
Media Contact:
Jodi Perkins
Amendola Communications, on behalf of ImpediMed
jperkins@acmarketingpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/impedimed-secures-15m-growth-capital-funding-302371333.html
SOURCE ImpediMed
FAQ
What is the value and terms of SWKH's funding to ImpediMed?
How many covered lives does ImpediMed's SOZO platform have through U.S. health payors?
What is the significance of the 2024 NABPC accreditation standards update for ImpediMed?
What unique FDA clearance does ImpediMed's SOZO platform hold?
